NasdaqCM:AXGNMedical Equipment
Axogen (AXGN) Valuation Check After FDA Avance Approval And New 2026 Growth Targets
Axogen (AXGN) just cleared a major regulatory hurdle, securing FDA approval for Avance as the first biologic therapeutic for peripheral nerve repair. The company also received 12 years of market exclusivity and issued new 2026 sales guidance.
See our latest analysis for Axogen.
The FDA approval, upsized equity raise and new 2026 guidance come after a period of mixed trading, with a 1-day share price return of 2.18% and a 90-day share price return of 11.34%, while the 1-year total shareholder...